CTOs on the Move

Eton Pharmaceuticals

www.etonpharma.com

 
Eton is an innovative pharmaceutical company that searches the world over for meaningful therapies that we can bring to patients living with rare diseases.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Xeris Pharmaceuticals

It`s all about the experience. Everything we do is about simplifying and making things better and easier. It`s about making a difference in people`s lives.

Meyer Pharmaceuticals (Main)

Meyer Pharmaceuticals (Main) is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Regenerative Processing Plant

Regenerative Processing Plant is a biotechnology company that manufactures various stem cell stimulants using patented D MAPPS technology. They offer a wide range of innovative high quality soft tissue and wound care products for tissue regeneration.

SpaLab

SpaLab is a San Marcos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

UroGen

UroGen Pharma is a biopharmaceutical company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. Our vision is grounded in our RTGel™ drug delivery technology platform, our promising pipeline, and a collaborative drive for bold results. Our existing technology: the RTGel drug delivery platform has the potential to be applied to a variety of unmet medical needs. RTGel reverse-thermal hydrogel is liquid at lower temperatures and converts to gel form at body temperature, offering the opportunity to make local therapy a more effective treatment. Our promising pipeline: Ranging from pre-clinical to Phase III, we currently have multiple candidates in our pipeline, which are furthering the study of potential treatment advances in urology, uro-oncology, and immunology. Our collaborative drive: We are part of a broad ecosystem of partners who are seeking to improve patient care; these connections are vital to our commitment to offer new pathways and advance solutions. We currently have an exclusive worldwide license agreement with Allergan™ to evaluate the RTGel platform, an early-stage feasibility agreement with Janssen Pharmaceuticals™, and are continually evaluating new opportunities.